LeMaitre Vascular Inc (LMAT) - Total Liabilities

Latest as of September 2025: $219.15 Million USD

Based on the latest financial reports, LeMaitre Vascular Inc (LMAT) has total liabilities worth $219.15 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does LeMaitre Vascular Inc generate cash to assess how effectively this company generates cash.

LeMaitre Vascular Inc - Total Liabilities Trend (2001–2024)

This chart illustrates how LeMaitre Vascular Inc's total liabilities have evolved over time, based on quarterly financial data. Check LMAT financial resilience to evaluate the company's liquid asset resilience ratio.

LeMaitre Vascular Inc Competitors by Total Liabilities

The table below lists competitors of LeMaitre Vascular Inc ranked by their total liabilities.

Company Country Total Liabilities
Aarti Industries Limited
NSE:AARTIIND
India Rs59.90 Billion
Worthington Steel Inc
NYSE:WS
USA $803.10 Million
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
China CN¥4.40 Billion
BaoViet Holdings
VN:BVH
Vietnam ₫266.30 Trillion
Werner Enterprises Inc
NASDAQ:WERN
USA $1.50 Billion
WK Kellogg Co
NYSE:KLG
USA $1.78 Billion
Cal-Comp Electronics (Thailand) Public Company Limited
BK:CCET
Thailand ฿54.15 Billion

Liability Composition Analysis (2001–2024)

This chart breaks down LeMaitre Vascular Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LMAT company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 13.58 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.58 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.37 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how LeMaitre Vascular Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for LeMaitre Vascular Inc (2001–2024)

The table below shows the annual total liabilities of LeMaitre Vascular Inc from 2001 to 2024.

Year Total Liabilities Change
2024-12-31 $214.53 Million +338.90%
2023-12-31 $48.88 Million +15.62%
2022-12-31 $42.27 Million +9.38%
2021-12-31 $38.65 Million -51.83%
2020-12-31 $80.24 Million +99.60%
2019-12-31 $40.20 Million +75.91%
2018-12-31 $22.85 Million +38.06%
2017-12-31 $16.55 Million +14.76%
2016-12-31 $14.42 Million +12.51%
2015-12-31 $12.82 Million -3.50%
2014-12-31 $13.29 Million -4.63%
2013-12-31 $13.93 Million +36.94%
2012-12-31 $10.17 Million +33.86%
2011-12-31 $7.60 Million -30.40%
2010-12-31 $10.92 Million +25.60%
2009-12-31 $8.69 Million +0.49%
2008-12-31 $8.65 Million -31.15%
2007-12-31 $12.56 Million +100.59%
2006-12-31 $6.26 Million -4.10%
2005-12-31 $6.53 Million +14.84%
2004-12-31 $5.69 Million +21.18%
2002-12-31 $4.69 Million -6.94%
2001-12-31 $5.04 Million --

About LeMaitre Vascular Inc

NASDAQ:LMAT USA Medical Instruments & Supplies
Market Cap
$2.54 Billion
Market Cap Rank
#6286 Global
#1877 in USA
Share Price
$112.04
Change (1 day)
+2.09%
52-Week Range
$79.12 - $117.39
All Time High
$117.39
About

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arte… Read more